121 related articles for article (PubMed ID: 17212733)
1. Pegylated interferon and ribavirin combination therapy for chronic hepatitis C in patients with congenital bleeding disorders: a single-centre experience.
Posthouwer D; Fischer K; De Heusden N; Mauser-Bunschoten EP
Haemophilia; 2007 Jan; 13(1):98-103. PubMed ID: 17212733
[TBL] [Abstract][Full Text] [Related]
2. Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.
Schaefer M; Hinzpeter A; Mohmand A; Janssen G; Pich M; Schwaiger M; Sarkar R; Friebe A; Heinz A; Kluschke M; Ziemer M; Gutsche J; Weich V; Halangk J; Berg T
Hepatology; 2007 Oct; 46(4):991-8. PubMed ID: 17668880
[TBL] [Abstract][Full Text] [Related]
3. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
[TBL] [Abstract][Full Text] [Related]
4. Comparison of low-dose pegylated interferon versus standard high-dose pegylated interferon in combination with ribavirin in patients with chronic hepatitis C with genotype 3: an Indian experience.
Sood A; Midha V; Hissar S; Kumar M; Suneetha PV; Bansal M; Sood N; Sakhuja P; Sarin SK
J Gastroenterol Hepatol; 2008 Feb; 23(2):203-7. PubMed ID: 17645472
[TBL] [Abstract][Full Text] [Related]
5. Early viral kinetics and treatment outcome in combination of high-dose interferon induction vs. pegylated interferon plus ribavirin for naive patients infected with hepatitis C virus of genotype 1b and high viral load.
Tsubota A; Arase Y; Someya T; Suzuki Y; Suzuki F; Saitoh S; Ikeda K; Akuta N; Hosaka T; Kobayashi M; Kumada H
J Med Virol; 2005 Jan; 75(1):27-34. PubMed ID: 15543591
[TBL] [Abstract][Full Text] [Related]
6. Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response.
Kamal SM; El Tawil AA; Nakano T; He Q; Rasenack J; Hakam SA; Saleh WA; Ismail A; Aziz AA; Madwar MA
Gut; 2005 Jun; 54(6):858-66. PubMed ID: 15888797
[TBL] [Abstract][Full Text] [Related]
7. Comparison of two PEG-interferon alpha-2b doses (1.0 or 1.5 microg/kg) combined with ribavirin in interferon-naïve patients with chronic hepatitis C and up to moderate fibrosis.
Meyer-Wyss B; Rich P; Egger H; Helbling B; Müllhaupt B; Rammert C; Gonvers JJ; Oneta C; Criblez D; Rossi L; Borovicka J; Meyenberger C; Arn M; Renner EL;
J Viral Hepat; 2006 Jul; 13(7):457-65. PubMed ID: 16792539
[TBL] [Abstract][Full Text] [Related]
8. [Experiences in antiviral treatment of chronic viral hepatitis B and C in Hungary (1998-2004)].
Pár A; Tornai I; Szalay F
Orv Hetil; 2007 May; 148(18):819-26. PubMed ID: 17468063
[TBL] [Abstract][Full Text] [Related]
9. [The role and possibilities of natural interferon treatment in chronic hepatitis C: experience with natural interferon treatment for patients barred from combined antiviral therapy because of the STOP rule].
Horváth G; Tolvaj G; Halász T; Stotz G
Orv Hetil; 2007 Aug; 148(33):1545-50. PubMed ID: 17686672
[TBL] [Abstract][Full Text] [Related]
10. Ribavirin suppresses erythroid differentiation and proliferation in chronic hepatitis C patients.
Ronzoni L; Aghemo A; Rumi MG; Prati G; Colancecco A; Porretti L; Monico S; Colombo M; Cappellini MD
J Viral Hepat; 2014 Jun; 21(6):416-23. PubMed ID: 24750239
[TBL] [Abstract][Full Text] [Related]
11. Pegylated interferon alfa-2b vs standard interferon alfa-2b, plus ribavirin, for chronic hepatitis C in HIV-infected patients: a randomized controlled trial.
Carrat F; Bani-Sadr F; Pol S; Rosenthal E; Lunel-Fabiani F; Benzekri A; Morand P; Goujard C; Pialoux G; Piroth L; Salmon-Céron D; Degott C; Cacoub P; Perronne C;
JAMA; 2004 Dec; 292(23):2839-48. PubMed ID: 15598915
[TBL] [Abstract][Full Text] [Related]
12. Gamma-glutamyltransferase and rapid virological response as predictors of successful treatment with experimental or standard peginterferon-alpha-2b in chronic hepatitis C non-responders.
Bergmann JF; Vrolijk JM; van der Schaar P; Vroom B; van Hoek B; van der Sluys Veer A; de Vries RA; Verhey E; Hansen BE; Brouwer JT; Janssen HL; Schalm SW; de Knegt RJ
Liver Int; 2007 Nov; 27(9):1217-25. PubMed ID: 17919233
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients.
Torriani FJ; Rodriguez-Torres M; Rockstroh JK; Lissen E; Gonzalez-García J; Lazzarin A; Carosi G; Sasadeusz J; Katlama C; Montaner J; Sette H; Passe S; De Pamphilis J; Duff F; Schrenk UM; Dieterich DT;
N Engl J Med; 2004 Jul; 351(5):438-50. PubMed ID: 15282351
[TBL] [Abstract][Full Text] [Related]
14. Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.
Baker RD; Dee D; Baker SS
J Clin Gastroenterol; 2007 Jan; 41(1):111-4. PubMed ID: 17198073
[TBL] [Abstract][Full Text] [Related]
15. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C.
McHutchison J; Sulkowski M
J Viral Hepat; 2008 Jul; 15(7):475-81. PubMed ID: 18363672
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of pegylated interferon/ribavirin combination in 'real world' patients with chronic hepatitis C virus infection.
Borroni G; Andreoletti M; Casiraghi MA; Ceriani R; Guerzoni P; Omazzi B; Terreni N; Salerno F
Aliment Pharmacol Ther; 2008 May; 27(9):790-7. PubMed ID: 18298638
[TBL] [Abstract][Full Text] [Related]
17. Treatment of genotype 1b HCV-related chronic hepatitis: efficacy and toxicity of three different interferon alfa-2b/ribavirin combined regimens in naive patients.
Scotto G; Fazio V; Palumbo E; Cibelli DC; Saracino A; Angarano G
New Microbiol; 2005 Jan; 28(1):23-9. PubMed ID: 15782623
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
[TBL] [Abstract][Full Text] [Related]
19. Response of hepatitis C genotype-4 naïve patients to 24 weeks of Peg-interferon-alpha2b/ribavirin or induction-dose interferon-alpha2b/ribavirin/amantadine: a non-randomized controlled study.
El-Zayadi AR; Attia M; Barakat EM; Badran HM; Hamdy H; El-Tawil A; El-Nakeeb A; Selim O; Saied A
Am J Gastroenterol; 2005 Nov; 100(11):2447-52. PubMed ID: 16279899
[TBL] [Abstract][Full Text] [Related]
20. Pegylated interferon alpha-2b plus ribavirin for the treatment of chronic hepatitis C in HIV-coinfected patients.
Voigt E; Schulz C; Klausen G; Goelz J; Mauss S; Schmutz G; Jessen H; Weitner L; Mutz A; Schranz D; Rockstroh JK;
J Infect; 2006 Jul; 53(1):36-42. PubMed ID: 16269184
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
